Caldera Health’s mission is to develop highly accurate prostate cancer diagnostic and prognostic tests. The tests analyse levels of selected RNA biomarkers. Together these form gene signatures that enable diagnosis of prostate cancer and prognosis of disease progression. A privately owned New Zealand biotech company has made huge progress in developing a replacement for the PSA prostate cancer test ComputerWorld Prostate cancer is the second most prevalent cancer, and current screening tests are inadequate. Caldera Health is developing a non-invasive test to accurately and reliably detect prostate cancer, and then determine the risk of aggressiveness. Caldera uses RNA biomarkers isolated from vesicles to accurately detect if cancer is present or not. Caldera Health is an active NZ biotech company, please follow our updates here. Caldera welcomes discussions with potential collaborators, partners, patients and with clinicians. Please get in touch!
We are Caldera Health
What they’re saying about us
What we do
Prostate Cancer
Diagnostics
Technologies
News
Connect with us
